Insulet (NASDAQ:PODD) Stock Gets Price Target Increase from Leerink Partners

Insulet (NASDAQ:PODD) had its target price upped by investment analysts at Leerink Partners from $143.00 to $167.00 in a research note issued on Thursday, Benzinga reports. The firm presently has a “market perform” rating on the medical instruments supplier’s stock. Leerink Partners‘s target price suggests a potential upside of 13.99% from the company’s previous close.

A number of other research firms also recently weighed in on PODD. Raymond James Financial reiterated an “outperform” rating and set a $180.00 target price on shares of Insulet in a report on Thursday, August 6th. Barclays upgraded Insulet to a “hold” rating in a research note on Wednesday, October 7th. Oppenheimer lowered Insulet from an “outperform” rating to a “market perform” rating in a research report on Wednesday, August 5th. Robert W. Baird set a $175.00 price target on Insulet in a research report on Thursday, August 6th. Finally, BTIG Research cut Insulet from a “buy” rating to a “neutral” rating in a research note on Thursday, August 6th. Twelve analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $185.38.

Insulet Trading Down 6.2%

Shares of PODD traded down $9.61 during trading hours on Thursday, reaching $146.51. 1,567,721 shares of the company traded hands, compared to its average volume of 1,380,594. The company’s fifty day moving average price is $141.97 and its two-hundred day moving average price is $176.65. The company has a market capitalization of $10.16 billion, a price-to-earnings ratio of 23.86, a price-to-earnings-growth ratio of 1.21 and a beta of 1.06. The company has a quick ratio of 1.83, a current ratio of 2.48 and a debt-to-equity ratio of 0.65. Insulet has a 12 month low of $126.40 and a 12 month high of $354.88.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Wednesday, November 4th. The medical instruments supplier reported $1.99 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.59 by $0.40. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The company had revenue of $842.00 million for the quarter, compared to analysts’ expectations of $832.63 million. During the same quarter in the previous year, the company earned $1.24 earnings per share. Insulet’s quarterly revenue was up 19.2% on a year-over-year basis. Equities research analysts predict that Insulet will post 6.75 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Insulet

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Diversified Trust Co increased its stake in shares of Insulet by 47.0% during the third quarter. Diversified Trust Co now owns 5,036 shares of the medical instruments supplier’s stock valued at $657,000 after purchasing an additional 1,611 shares in the last quarter. Allworth Financial LP lifted its holdings in shares of Insulet by 2.3% during the third quarter. Allworth Financial LP now owns 3,104 shares of the medical instruments supplier’s stock valued at $405,000 after purchasing an additional 71 shares during the last quarter. Fifth Third Bancorp boosted its position in shares of Insulet by 21.3% in the 3rd quarter. Fifth Third Bancorp now owns 64,540 shares of the medical instruments supplier’s stock worth $8,421,000 after purchasing an additional 11,334 shares in the last quarter. Maryland State Retirement & Pension System boosted its position in shares of Insulet by 22.5% in the 3rd quarter. Maryland State Retirement & Pension System now owns 4,176 shares of the medical instruments supplier’s stock worth $545,000 after purchasing an additional 768 shares in the last quarter. Finally, Ritholtz Wealth Management purchased a new stake in shares of Insulet in the 3rd quarter worth approximately $276,000.

Key Headlines Impacting Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Several firms raised targets and maintained bullish ratings: RBC lifted its target to $180 and kept an Outperform rating, Bernstein raised its target to $200 and kept Outperform, and Canaccord reiterated Buy with a $179 target. RBC target update Canaccord rating update
• Positive Sentiment: Other analysts also raised targets, while commentary described Insulet as potentially undervalued and highlighted its $1 billion buyback. Recent quarterly results provide support: the company beat earnings and revenue estimates, with revenue up 19.2% year over year, according to the supplied company data. Valuation and buyback article
• Neutral Sentiment: UBS, JPMorgan, Citi, Barclays, Wells Fargo and Leerink all increased their price targets, generally retaining Neutral, Equal Weight or Market Perform ratings. The higher targets are supportive, but the largely unchanged ratings suggest analysts see risks as well as recovery potential.
• Negative Sentiment: Analyst discussion flagged a more conservative 2027 outlook and competition, tempering optimism about Insulet’s growth. Coverage characterized the outlook as moderate despite international strength and an innovation pipeline. RBC outlook article Q3 growth analysis

Insulet Company Profile

Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company’s primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.